June 2019 - Volume 3 - Issue - Contributor Index

Author:
O'Brien, S.

EMERGING CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL): S868

Bannerji, R.; Arnason, J.; Advani, R.; More

HemaSphere. 3:388-389, June 2019.

EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED IN THE INO-VATE TRIAL: OUTCOMES BY SALVAGE-TREATMENT PHASE: PS950

Jabbour, E.; Stelljes, M.; Advani, A. S.; More

HemaSphere. 3:428, June 2019.

Author:
O'Brien, S. M.

PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B-CELL MALIGNANCIES: PS1148

Allan, J. N.; Patel, K.; Mato, A. R.; More

HemaSphere. 3:520, June 2019.

Author:
O'Byrne, S.
Author:
O'Connell, A.

GLASDEGIB WITH LDAC IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNSUITABLE FOR INTENSIVE CHEMOTHERAPY: EFFECTS ON TRANSFUSIONS AND MARROW RECOVERY VS LDAC ALONE: PF272

Wang, E. S.; Heuser, M.; Montesinos, P.; More

HemaSphere. 3:87, June 2019.

CLINICAL BENEFIT OF GLASDEGIB PLUS LOW-DOSE CYTARABINE IN PATIENTS WITH DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA: LONG-TERM ANALYSIS OF A PHASE 2 RANDOMIZED TRIAL: PS1029

Heuser, M.; Fiedler, W.; Sekeres, M. A.; More

HemaSphere. 3:464-465, June 2019.

Author:
O'Connor, D.

EXCELLENT RESPONSE TO BLINATUMOMAB IN REFRACTORY B LINEAGE ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN AND YOUNG ADULTS AFTER DEBULKING CHEMOTHERAPY TO ACHIEVE PARTIAL REMISSION: PS948

Clesham, K.; Rao, V.; Bartram, J.; More

HemaSphere. 3:427, June 2019.

Author:
O'Connor, O.
Author:
O'Connor, O. A.

THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS: PS1070

Illidge, T.; Pro, B.; Trümper, L.; More

HemaSphere. 3:484-485, June 2019.

Author:
O'Dwyer, K. M.

KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3: PS945

Shah, B. D.; Bishop, M. R.; Oluwole, O. O.; More

HemaSphere. 3:426, June 2019.

Author:
O'Dwyer, M.

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA: PF592

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3:248-249, June 2019.

Author:
O'Hare, T.
Author:
O'Keefe, K.
Author:
O'Mara, E.
Author:
O'Marcaigh, A.

DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML): PF677

Niemeyer, C. M.; Flotho, C.; Lipka, D. B.; More

HemaSphere. 3:292, June 2019.

Author:
O'Rourke, C.

IMR-687, A HIGHLY SELECTIVE PHOSPHODIESTERASE 9 INHIBITOR (PDE9I), DEMONSTRATES PRELIMINARY EVIDENCE OF ACTIVITY ON RED AND WHITE CELL BIOMARKERS IN A PH-2A INTERIM ANALYSIS: S854

Andemariam, B.; Johnson, K.; Gordeuk, V.; More

HemaSphere. 3:381-382, June 2019.

Author:
O'Rourke, L.

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK: PF591

Dimopoulos, M. A.; San-Miguel, J.; White, D.; More

HemaSphere. 3:247-248, June 2019.

RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA: S823

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3:364, June 2019.

Author:
Oakervee, H.
Author:
Oakes, C.
Author:
Oakey, R.
Author:
Obara, N.

THE RELATIONSHIP BETWEEN THE PRETREATMENT PNH CLONE SIZE AND CLINICAL COURSE IN PATIENTS WITH BONE MARROW FAILURE SYNDROMES: INTERIM ANALYSIS OF JAPANESE MULTICENTER PROSPECTIVE STUDY: PS1115

Ueda, Y.; Hosokawa, K.; Ishiyama, K.; More

HemaSphere. 3:504-505, June 2019.

TARGETING T-CELL RECEPTOR SIGNALING PATHWAY BY DASATINIB IN RELAPSED/REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: PS1308

Kiyoki, Y.; Sakata-Yanagimoto, M.; Nguyen, T. B.; More

HemaSphere. 3:597, June 2019.

Author:
Oberg, H.-H.
Author:
Obergan, T.
Author:
Oberic, L.

CLINICAL EFFICACY OF THE RIBVD REGIMEN FOR REFRACTORY/RELAPSED (R/R) MANTLE CELL LYMPHOMA (MCL) PATIENTS: A RETROSPECTIVE STUDY OF THE LYSA GROUP: PF482

Regny, C.; Oberic, L.; guillaume, M.; More

HemaSphere. 3:193, June 2019.

Author:
Obermüller, J.
Author:
Obr, A.

UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS: PF296

Duell, J.; Maddocks, K.; Barca, González E.; More

HemaSphere. 3:100, June 2019.

Author:
Obreja, M.
Author:
Obuchova, T.
Author:
Obukhova, T.

RESULTS OF TREATMENT PATIENTS OF MANTLE CELL LYMPHOMA DEPENDING ON THE MUTATIONAL STATUS OF THE TP53 GENE: PB2016

Koroleva, D.; Zvonkov, E.; Gabeeva, N.; More

HemaSphere. 3:912, June 2019.

Author:
Ocak, S.
Author:
Ochi, Y.

NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA: PS983

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3:442, June 2019.

Author:
Ochiai, T.
Author:
Ochirova, O.
Author:
Ochoa, P.

OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM: PS1402

Peña, C.; Schutz, N. P.; Bove, V.; More

HemaSphere. 3:643-644, June 2019.

Author:
Ochrem, B.
Author:
Ocias, Frans L.

THREE-YEAR ANALYSIS OF THE DALIAH TRIAL - A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA-2 VS. HYDROXYUREA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: S1609

Knudsen, T. A.; Hansen, Lund D.; Ocias, Frans L.; More

HemaSphere. 3:741-742, June 2019.

IMPACT OF SMOKING ON JAK2V617F ALLELE BURDEN AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS TREATED WITH PEGYLATED INTERFERON ALPHA-2 OR HYDROXYUREA IN THE DALIAH TRIAL: PB2210

Patel, D.; Knudsen, Alma T.; Hansen, Lund D.; More

HemaSphere. 3:990-991, June 2019.

Author:
Ocio, E.

ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR: PF608

Pour, L.; Efebera, Y. A.; Granell, M.; More

HemaSphere. 3:257-258, June 2019.

CURATIVE STRATEGY (GEM-CESAR) FOR HIGH-RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT-ASCT, CONSOLIDATION WITH KRD AND MAINTENANCE WITH RD: S871

Mateos, M.-V.; Martínez-López, J.; Rodríguez-Otero, P.; More

HemaSphere. 3:390, June 2019.

EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA. RETROSPECTIVE ANALYSIS IN OUR CENTER: PB2350

Romero, Gonzalez Y.; Mora, J.; Cortes, M. A.; More

HemaSphere. 3:1047, June 2019.

Author:
Ocio, E. M.

HEAVY&LIGHT CHAIN MONITORING IN HIGH RISK SMOLDERING MULTIPLE MYELOMA PATIENTS INCLUDED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MINIMAL RESIDUAL DISEASE IMWG RESPONSE ASSESSMENT: PF609

Puig, N.; Contreras, T.; Paiva, B.; More

HemaSphere. 3:258, June 2019.

DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS: PS1352

Puig, N.; Paíno, T.; Pérez, J. J.; More

HemaSphere. 3:617-618, June 2019.

RECOVERY OF POLICLONAL IMMUNOGLOBULINS AS A PREDICTOR FACTOR OF INCREASED PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR ASCT: PS1398

Dávila, J.; González-Calle, V.; Puig, N.; More

HemaSphere. 3:641-642, June 2019.

Author:
Oda, T.

EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY: PF184

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3:44, June 2019.

Author:
Odame, I.

PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS): S839

Navada, S. C.; Garcia-Manero, G.; Atallah, E.; More

HemaSphere. 3:373-374, June 2019.

Author:
Oddolo, D.

TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS‘ CHARACTERISTICS IN MULTIPLE MYELOMA: PF579

Muccio, V. E.; Gilestro, M.; Saraci, E.; More

HemaSphere. 3:241-242, June 2019.

Author:
Odenike, O.
Author:
Odero, M. D.
Author:
Odievre, M.-H.
Author:
Odilov, A.
Author:
Odinius, T.
Author:
Odom, D.

HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE-MM3: PF626

Schjesvold, F.; Goldschmidt, H.; Maisnar, V.; More

HemaSphere. 3:266-267, June 2019.

Author:
Oehler, V. G.

SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS: PF253

Howard, N. P.; Halpern, A. B.; Othus, M.; More

HemaSphere. 3:78, June 2019.

Author:
Oerlemans, S.
Author:
Oevermann, L.
Author:
Offidani, M.

OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS: PF602

Montefusco, V.; Gay, F.; Spada, S.; More

HemaSphere. 3:254-255, June 2019.

CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS: S872

Gay, F.; Cerrato, C.; Scalabrini, Rota D.; More

HemaSphere. 3:390-391, June 2019.

Author:
Offner, F.

EFFICACY WAS IMPROVED WITH LENALIDOMIDE/RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH FOLLICULAR LYMPHOMA IRRESPECTIVE OF POD24 STATUS IN THE PHASE III AUGMENT STUDY: PF483

Leonard, J. P.; Trneny, M.; Izutsu, K.; More

HemaSphere. 3:193-194, June 2019.

PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT): PS1252

Gribben, J.; Trneny, M.; Izutsu, K.; More

HemaSphere. 3:571-572, June 2019.

POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: PS1262

Thieblemont, C.; Leonard, J. P.; Trneny, M.; More

HemaSphere. 3:577-578, June 2019.

Author:
Ofiteru, G.

CHARACTERISTICS OF DIAGNOSIS AND TREATMENT OUTCOME IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 60 YEARS-ANALYSES OF SINGLE CENTER: PB1760

Popov, V.; Georgescu, D.; Andreescu, M.; More

HemaSphere. 3:808-809, June 2019.

Author:
Ofran, Y.
Author:
Ogasawara, M.
Author:
Ogata, K.

SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION: PS1435

Kato, S.; Maekawa, T.; Ogata, K.; More

HemaSphere. 3:661-662, June 2019.

Author:
Ogata, M.
Author:
Ogata, Y.

REDUCED-INTENSITY IMMUNOCHEMOTHERAPY WITHOUT VINCRISTINE IN ELDERLY PATIENTS OLDER THAN 80 YEARS OLD WITH DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL: PF301

Yoshida, I.; Suehiro, Y.; Hirabayashi, Y.; More

HemaSphere. 3:102-103, June 2019.

Author:
Ogawa, M.

PATIENT PREFERENCES FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS OF A PATIENT SURVEY OF RAVULIZUMAB (ALXN1210) AND ECULIZUMAB: PF734

Peipert, J. D.; Kulasekararaj, A.; Gaya, A.; More

HemaSphere. 3:321, June 2019.

Author:
Ogawa, N.
Author:
Ogawa, S.

NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS: S135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

NOVEL MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGET IN ACUTE ERYTHROID LEUKEMIA: PS983

Takeda, J.; Shih, L.-Y.; Yoshida, K.; More

HemaSphere. 3:442, June 2019.

Show: